VRTX · 10-Q · 2026Q3 · Full report

Market Demand Trends

VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 60 · Surprise 40

Vertex reported continued growth in cystic fibrosis (CF) therapies and expanding contributions from CASGEVY, JOURNAVX, and PALSONIFY, with total product revenues up 11% in the first nine months of 2026. CF remains the primary source of product revenue, and the company expects the number of people taking its CF medicines to grow through younger-patient treatment, increased survival, new approvals, and geographic expansion. ALYFTREK reimbursement expanded to seven additional countries in the third quarter, bringing the total to 32. U.S. revenue increased 9% and ex-U.S. revenue increased 13% in the first nine months, with ex-U.S. growth reflecting CF performance across multiple geographies and CASGEVY uptake.